Teriflunomide: a review of its use in relapsing multiple sclerosis.

about

Teriflunomide and its mechanism of action in multiple sclerosis.Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.

P2860

Q37730005-2924627B-E09E-4048-8E46-D1753ADB4810 Q38534132-13CDED5F-F0FB-408B-9479-D216FC37AB65 Q39032639-5A3C9B54-C876-489F-92AD-FA7A6E61E637

P2860

Teriflunomide: a review of its use in relapsing multiple sclerosis.

Item

http://www.wikidata.org/entity/Q38160410

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Teriflunomide: a review of its use in relapsing multiple sclerosis.

@en

type

Item

label

Teriflunomide: a review of its use in relapsing multiple sclerosis.

@en

prefLabel

Teriflunomide: a review of its use in relapsing multiple sclerosis.

@en

P1476

Teriflunomide: a review of its use in relapsing multiple sclerosis.

@en

P2860

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

Leflunomide: a review of its use in active rheumatoid arthritis.

Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.

The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis.

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.

Multiple sclerosis therapies: molecular mechanisms and future.

Pathophysiology of multiple sclerosis and the place of teriflunomide.

P2888

s40263-013-0118-2

P304

1103-1123

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40263-013-0118-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Karly Garnock-Jones

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24198223

http://www.w3.org/2001/XMLSchema#string

Teriflunomide: a review of its use in relapsing multiple sclerosis.

about

P2860

P2860

Teriflunomide: a review of its use in relapsing multiple sclerosis.

description

name

type

label

prefLabel

P1433

P1476

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698